# Maxpro Capital Acquisition Corp. (JMAC)

Source: https://www.quantisnow.com/company/JMAC
Generated: 2026-11-11T05:46:37.778Z

- Ticker: JMAC
- Exchange: NASDAQ
- Sector: Industrials
- Industry: Consumer Electronics/Appliances
- IPO year: 2021

## About

Jade Mountain Acquisition Corp. focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2021 and is based in Taipei City, Taiwan.

## Latest JMAC news and filings

- 2023-04-11 18:07 UTC [SEC Schedule 13G] [SEC Form SC 13G/A filed by Maxpro Capital Acquisition Corp. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13ga-filed-by-maxpro-capital-acquisition-corp-4322208)
- 2023-04-10 13:00 UTC [SEC Form 15-12G filed by Maxpro Capital Acquisition Corp.](https://www.quantisnow.com/insight/sec-form-15-12g-filed-by-maxpro-capital-acquisition-corp-4315285)
- 2023-03-31 20:00 UTC [SEC Form 10-K] [SEC Form 10-K filed by Maxpro Capital Acquisition Corp.](https://www.quantisnow.com/insight/sec-form-10-k-filed-by-maxpro-capital-acquisition-corp-4281318)
- 2023-03-30 12:14 UTC [Market Insight] [Apollomics, A Company Developing Novel Oncology Therapies To Address Difficult-To-Treat Cancers, Announces Closing Of Business Combination And Listing On Nasdaq](https://www.quantisnow.com/insight/apollomics-a-company-developing-novel-oncology-therapies-to-address-difficult-to-treat-4269684)
- 2023-03-30 12:09 UTC [SEC Form 8-K] [Maxpro Capital Acquisition Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/maxpro-capital-acquisition-corp-filed-sec-form-8-k-entry-into-4269659)
- 2023-03-30 12:00 UTC [Public Offering] [Apollomics, a Company Developing Novel Oncology Therapies to Address Difficult-to-Treat Cancers, Announces Closing of Business Combination and Listing on Nasdaq](https://www.quantisnow.com/insight/apollomics-a-company-developing-novel-oncology-therapies-to-address-difficult-to-treat-4269552)
- 2023-03-30 05:37 UTC [Market Insight] [Reported Late Wednesday March 29, Apollomics Announces Completion Of Business Combination With Maxpro Capital Acquisition Corp. And Listing On Nasdaq; Expected To Commence Trading On March 30, 2023, On The Nasdaq Capital Market Under The Symbols "APLM"](https://www.quantisnow.com/insight/reported-late-wednesday-march-29-apollomics-announces-completion-of-business-4268168)
- 2023-03-29 21:55 UTC [SEC Form 4] [SEC Form 4 filed by Chen Yi-Kuei (Alex)](https://www.quantisnow.com/insight/sec-form-4-filed-by-chen-yi-kuei-alex-4267725)
- 2023-03-29 21:36 UTC [SEC Form 4] [SEC Form 4 filed by Wu Soushan](https://www.quantisnow.com/insight/sec-form-4-filed-by-wu-soushan-4267677)
- 2023-03-29 21:31 UTC [SEC Form 4] [SEC Form 4 filed by Gau Wey - Chuan](https://www.quantisnow.com/insight/sec-form-4-filed-by-gau-wey---chuan-4267665)
- 2023-03-29 21:12 UTC [SEC Form 4] [SEC Form 4 filed by Georges Noha](https://www.quantisnow.com/insight/sec-form-4-filed-by-georges-noha-4267473)
- 2023-03-29 20:59 UTC [SEC Form 4] [SEC Form 4 filed by Mp One Investment Llc](https://www.quantisnow.com/insight/sec-form-4-filed-by-mp-one-investment-llc-4267300)
- 2023-03-29 20:56 UTC [SEC Form 4] [SEC Form 4 filed by Chen Hong - Jung (Moses)](https://www.quantisnow.com/insight/sec-form-4-filed-by-chen-hong---jung-moses-4267257)
- 2023-03-29 20:24 UTC [SEC Form 25-NSE filed by Maxpro Capital Acquisition Corp.](https://www.quantisnow.com/insight/sec-form-25-nse-filed-by-maxpro-capital-acquisition-corp-4266874)
- 2023-03-29 20:24 UTC [SEC Form 4] [SEC Form 4 filed by Yung-Fong Song](https://www.quantisnow.com/insight/sec-form-4-filed-by-yung-fong-song-4266869)
- 2023-03-23 20:50 UTC [Market Insight] [Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Are Secretly Monitoring But Not Talking About Yet](https://www.quantisnow.com/insight/benzingas-stock-whisper-index-5-stocks-investors-are-secretly-monitoring-4242780)
- 2023-03-22 17:56 UTC [Market Insight] [Why Edible Garden Shares Are Trading Lower By Over 26%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session](https://www.quantisnow.com/insight/why-edible-garden-shares-are-trading-lower-by-over-26-4235677)
- 2023-03-22 14:09 UTC [Market Insight] [US Stocks Edge Lower Ahead Of Fed Decision; Nike Earnings Top Estimates](https://www.quantisnow.com/insight/us-stocks-edge-lower-ahead-of-fed-decision-nike-earnings-4234478)
- 2023-03-22 12:07 UTC [Market Insight] [Why GameStop Shares Are Trading Higher By Around 44%; Here Are 20 Stocks Moving Premarket](https://www.quantisnow.com/insight/why-gamestop-shares-are-trading-higher-by-around-44-here-4233407)
- 2023-03-21 20:07 UTC [SEC Form 8-K] [Maxpro Capital Acquisition Corp. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Other Events](https://www.quantisnow.com/insight/maxpro-capital-acquisition-corp-filed-sec-form-8-k-submission-of-4230883)
- 2023-03-21 16:53 UTC [Market Insight] [Why Citi Trends Shares Are Trading Lower By Over 14%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session](https://www.quantisnow.com/insight/why-citi-trends-shares-are-trading-lower-by-over-14-4229866)
- 2023-03-17 16:49 UTC [Market Insight] [Why Baidu Shares Are Trading Higher By More Than 6%? Here Are Other Stocks Moving In Friday's Mid-Day Session](https://www.quantisnow.com/insight/why-baidu-shares-are-trading-higher-by-more-than-6-4217823)
- 2023-02-14 21:34 UTC [SEC Schedule 13G] [SEC Form SC 13G/A filed by Maxpro Capital Acquisition Corp. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13ga-filed-by-maxpro-capital-acquisition-corp-4064426)
- 2023-02-14 21:25 UTC [SEC Schedule 13G] [SEC Form SC 13G/A filed by Maxpro Capital Acquisition Corp. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13ga-filed-by-maxpro-capital-acquisition-corp-4064009)
- 2023-02-13 21:07 UTC [SEC Schedule 13G] [SEC Form SC 13G/A filed by Maxpro Capital Acquisition Corp. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13ga-filed-by-maxpro-capital-acquisition-corp-4050233)
- 2023-02-10 12:07 UTC [SEC Form 8-K] [Maxpro Capital Acquisition Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits](https://www.quantisnow.com/insight/maxpro-capital-acquisition-corp-filed-sec-form-8-k-entry-into-4036920)
- 2023-01-13 21:37 UTC [SEC Form 425] [SEC Form 425 filed by Maxpro Capital Acquisition Corp.](https://www.quantisnow.com/insight/sec-form-425-filed-by-maxpro-capital-acquisition-corp-3911883)
- 2023-01-13 21:32 UTC [SEC Form 8-K] [Maxpro Capital Acquisition Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/maxpro-capital-acquisition-corp-filed-sec-form-8-k-entry-into-3911835)
- 2023-01-13 21:14 UTC [Market Insight] [Maxpro Capital Acquisition Confirms Additional Funding, Extension Of Deadline To Complete Initial Business Combination](https://www.quantisnow.com/insight/maxpro-capital-acquisition-confirms-additional-funding-extension-of-deadline-to-3911582)
- 2023-01-13 21:13 UTC [Public Offering] [Maxpro Capital Acquisition Corp. Confirms Additional Funding and Extension of Deadline to Complete Initial Business Combination](https://www.quantisnow.com/insight/maxpro-capital-acquisition-corp-confirms-additional-funding-and-extension-of-3911573)
- 2023-01-10 21:31 UTC [SEC Form 425] [SEC Form 425 filed by Maxpro Capital Acquisition Corp.](https://www.quantisnow.com/insight/sec-form-425-filed-by-maxpro-capital-acquisition-corp-3897014)
- 2023-01-10 21:24 UTC [Market Insight] [Maxpro Capital Acquisition Announces Extension To Deadline To Complete Business Combination, Says Sponsor Requested To Extend Date By Which Co. Has To Consummate Business Combination From Jan. 13 To Apr. 13](https://www.quantisnow.com/insight/maxpro-capital-acquisition-announces-extension-to-deadline-to-complete-business-3896924)
- 2023-01-10 21:23 UTC [SEC Form 8-K] [Maxpro Capital Acquisition Corp. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/maxpro-capital-acquisition-corp-filed-sec-form-8-k-other-events-3896921)
- 2023-01-10 21:07 UTC [Market Chatter] [Maxpro Capital Acquisition Corp. Announces Extension To Deadline To Complete Business Combination](https://www.quantisnow.com/insight/maxpro-capital-acquisition-corp-announces-extension-to-deadline-to-complete-3896677)
- 2023-01-10 21:05 UTC [Public Offering] [Maxpro Capital Acquisition Corp. Announces Extension to Deadline to Complete Business Combination](https://www.quantisnow.com/insight/maxpro-capital-acquisition-corp-announces-extension-to-deadline-to-complete-3896599)
- 2022-11-28 21:05 UTC [SEC Form 8-K] [Maxpro Capital Acquisition Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Financial Statements and Exhibits](https://www.quantisnow.com/insight/maxpro-capital-acquisition-corp-filed-sec-form-8-k-entry-into-3737896)
- 2022-11-15 13:02 UTC [Market Chatter] [Apollomics Inc. Receives FDA Orphan Drug Designation For Vebreltinib For Treatment Of Non-Small Cell Lung Cancer With MET Genomic Tumor Aberrations](https://www.quantisnow.com/insight/apollomics-inc-receives-fda-orphan-drug-designation-for-vebreltinib-for-3687465)
- 2022-11-15 13:00 UTC [Public Offering] [Apollomics Inc. Receives FDA Orphan Drug Designation for Vebreltinib (APL-101) for Treatment of Non-Small Cell Lung Cancer with MET Genomic Tumor Aberrations](https://www.quantisnow.com/insight/apollomics-inc-receives-fda-orphan-drug-designation-for-vebreltinib-apl-101-3687289)
- 2022-11-02 20:56 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Maxpro Capital Acquisition Corp.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-maxpro-capital-acquisition-corp-3620590)
- 2022-10-14 20:59 UTC [SEC Form 8-K] [Maxpro Capital Acquisition Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/maxpro-capital-acquisition-corp-filed-sec-form-8-k-entry-into-3535114)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/JMAC
- Earnings history: https://www.quantisnow.com/earnings/JMAC
- Dividend history: https://www.quantisnow.com/dividends/JMAC
- Insider transactions: https://www.quantisnow.com/insiders/JMAC
- Options chain: https://www.quantisnow.com/options/JMAC
- SEC 8-K filings only: https://www.quantisnow.com/company/JMAC/8-k
- RSS and alerts for JMAC: https://www.quantisnow.com/docs/rss-feeds.md